flanders.bio is an independent life sciences cluster organisation based in Flanders, Belgium

flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.

News from flanders.bio and its members

Biocartis Group NV: Studies on Idylla(TM) MSI and RAS liquid biopsy tests to be presented at ESMO congress

Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that two studies, one treatment outcome study[1] on the Idylla(TM) ctKRAS and ctNRAS-BRAF Mutation Tests (CE-IVD) and one[2] on the performance of the prototype Idylla(TM) MSI test, have been selected for presentation at the renowned European Society for Medical Oncology (ESMO) congress. The ESMO congress is considered the most influential annual meeting for oncology professionals in Europe and takes place between 19-23 October 2018 in Munich, Germany.

19 October 18 Read more

Oxurion NV Business Update - Q3 2018

Oxurion NV (Euronext Brussels: OXUR - formerly known as ThromboGenics), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, today issues a business update for the three-month period ending 30 September 2018.

Oxurion is developing a competitive pipeline of disease modifying drug candidates for diabetic eye disease, particularly diabetic retinopathy (DR) and diabetic macular edema (DME).

Bone Therapeutics announces single intra-articular injection of viscosupplement JTA-004 delivered higher pain reduction than the reference in first study in knee osteoarthritis

The bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces results of the first efficacy study of the Company’s enhanced viscosupplement, JTA-004, in patients with moderate symptomatic knee osteoarthritis, supporting future clinical development of the product.

Shareholder Transparency Declaration MDxHealth

MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), announced that it received on October 12, 2018 the following notification of significant shareholdings in accordance with the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "Belgian Transparency Act").

flanders.bio events, trainings & international missions

Strategic Partners